A Phase 3 interventional study of Ivermectin 1% cream and Metronidazole 0.75% cream in Papulopustular Rosacea, sponsored by Galderma R&D. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-10-28.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing ivermectin in Rosacea — none open to participants now, none under way, none of them phase 3. Ivermectin · Rosacea.
Among the 11 studies testing ivermectin in Rosacea, this one has the largest enrollment, is the only one that started in 2012, is one of 6 in phase 3, and was the 3rd registered.
233 studies on the registry are indexed under Rosacea; 22 are open to participants now.
Browse Rosacea studies →None of the 11 studies testing ivermectin in Rosacea is open now. The open studies under Rosacea, anywhere →
Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →
Of the 16 Rosacea studies recruiting now, 9 (56%) set no upper age limit and 6 (38%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 2 · Phase 3 6 · Phase 4 1
First in 2011; this study’s year is marked. 1 started in 2012.
This study's enrollment of 962 is above the median of 61 across 200 interventional studies indexed under Rosacea.
Median enrollment 486 across the 11 interventional studies. Of the 10 that completed or were terminated, 6 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 11 have an industry lead sponsor. The 8 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
28 studies in Rosacea by Galderma Group AG: none open now, none under way, none of them phase 3. Of 28 finished, 21 (75%) have results posted.
Among the 28 studies in Rosacea by Galderma Group AG, this one is the 2nd largest by enrollment of the 24 interventional ones that give a count, is one of 4 that started in 2012, is one of 11 in phase 3, and was the 17th registered.
Galderma Group AG’s Rosacea studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing ivermectin in Rosacea, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 28 in Rosacea:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Study objectives:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Ivermectin 1% cream
Drug: Metronidazole 0.75% cream
Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
Also known as: Soolantra
Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
Also known as: Metronidazole
Percent Change in Inflammatory Lesions From Baseline to Week 16
Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period
Time frame: Baseline and Week 16
Time to Relapse
Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.
Time frame: Week 16 up to Week 52
| Milestone | Ivermectin | Metronidazole 0.75% Cream |
|---|---|---|
| Started | 478 | 484 |
| Completed | 446 | 456 |
| Not completed | 32 | 28 |
| Milestone | Ivermectin | Metronidazole 0.75% Cream |
|---|---|---|
| Started | 399 | 358 |
| Completed | 366 | 326 |
| Not completed | 33 | 32 |
Efficacy of Ivermectin versus Metronidazole as determined by the percent change in inflammatory lesions after a 16-week treatment period
| percentage of change | Ivermectin | Metronidazole 0.75% Cream |
|---|---|---|
| Percent Change in Inflammatory Lesions From Baseline to Week 16 | -83 ± 26 | -73.7 ± 39.7 |
Relapse define as time elapsed between Week 16 and first reoccurrence of Investigator Global assessement (IGA) at '2 (mild)' , '3 (moderate)' or '4 (severe)'.
| Median days to relapse | CD5024 | Metronidazole 0.75% Cream |
|---|---|---|
| Time to Relapse | 115 (113 to 165) | 85 (85 to 113) |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ivermectin 1% Cream Period A | — | 8/478 (1.7%) | 101/478 (21.1%) |
| Metronidazole 0.75% Cream Period A | — | 5/484 (1%) | 100/484 (20.7%) |
| Ivermectin 1% Cream Period B | — | 10/399 (2.5%) | 110/399 (27.6%) |
| Metronidazole 0.75% Cream Period B | — | 11/359 (3.1%) | 91/359 (25.3%) |
| Event | Ivermectin 1% Cream Period A | Metronidazole 0.75% Cream Period A | Ivermectin 1% Cream Period B | Metronidazole 0.75% Cream Period B |
|---|---|---|---|---|
| Hypertensive CrisisVascular disorders | 1/478 | 0/484 | 0/399 | 2/359 |
| Coronary Artery DiseaseCardiac disorders | 0/478 | 1/484 | 0/399 | 1/359 |
| Anal FistulaGastrointestinal disorders | 0/478 | 0/484 | 0/399 | 1/359 |
| ErysipelasInfections and infestations | 0/478 | 0/484 | 0/399 | 1/359 |
| ParonychiaInfections and infestations | 0/478 | 0/484 | 0/399 | 1/359 |
| Respiratory Tract Infection BacterialInfections and infestations | 0/478 | 0/484 | 0/399 | 1/359 |
| OsteoathritisMusculoskeletal and connective tissue disorders | 0/478 | 0/484 | 1/399 | 1/359 |
| Ischaemic StrokeNervous system disorders | 0/478 | 0/484 | 1/399 | 1/359 |
| Ectopic PregnancyPregnancy, puerperium and perinatal conditions | 0/478 | 0/484 | 0/399 | 1/359 |
| Colon CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/478 | 0/484 | 0/399 | 1/359 |
| Event | Ivermectin 1% Cream Period A | Metronidazole 0.75% Cream Period A | Ivermectin 1% Cream Period B | Metronidazole 0.75% Cream Period B |
|---|---|---|---|---|
| NasopharingitisInfections and infestations | 32/478 | 29/484 | 37/399 | 39/359 |
| HeadacheNervous system disorders | 15/478 | 11/484 | 5/399 | 4/359 |
| InfluenzaInfections and infestations | 9/478 | 10/484 | 12/399 | 6/359 |
| HypertensionVascular disorders | 6/478 | 4/484 | 4/399 | 7/359 |
| Oral HerpesInfections and infestations | 3/478 | 5/484 | 7/399 | 3/359 |
| PharyngitisInfections and infestations | 3/478 | 4/484 | 5/399 | 6/359 |
| Back PainMusculoskeletal and connective tissue disorders | 7/478 | 4/484 | 6/399 | 5/359 |
| Urinary Tract InfectionInfections and infestations | 0/478 | 1/484 | 2/399 | 5/359 |
| BronchitisInfections and infestations | 6/478 | 4/484 | 4/399 | 3/359 |
| Upper Respiratory Tract InfectionInfections and infestations | 6/478 | 4/484 | 1/399 | 0/359 |
| Age, Categorical(Participants) | Ivermectin | Metronidazole 0.75% Cream | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 394 | 398 | 792 |
| >=65 years | 84 | 86 | 170 |
| Sex: Female, Male(Participants) | Ivermectin | Metronidazole 0.75% Cream | Total |
|---|---|---|---|
| Female | 311 | 316 | 627 |
| Male | 167 | 168 | 335 |
| Region of Enrollment(participants) | Ivermectin | Metronidazole 0.75% Cream | Total |
|---|---|---|---|
| Czech Republic | 40 | 40 | 80 |
| Russian Federation | 39 | 35 | 74 |
| Romania | 57 | 52 | 109 |
| Hungary | 76 | 84 | 160 |
| Ukraine | 30 | 30 | 60 |
| Poland | 57 | 57 | 114 |
| United Kingdom | 16 | 19 | 35 |
| Bulgaria | 20 | 17 | 37 |
| France | 31 | 36 | 67 |
| Germany | 112 | 114 | 226 |
The record gives a start of Apr 2012, a primary completion of Dec 2013 and a completion of Dec 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2015, 1 year 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ivermectin